Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 14/20 | 0.53 |
| ▸ | CDK2 | P24941 | 10/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.45 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | CLK3 | P49761 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15799252 | 1.00 | CDK7 (0.53) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799299 | 1.00 | CDK7 (0.53) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799367 | 0.91 | CDK7 (0.49) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799366 | 0.91 | CDK7 (0.49) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799368 | 0.91 | CDK7 (0.49) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799466 | 0.90 | CDK7 (0.52) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799463 | 0.90 | CDK7 (0.52) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799468 | 0.90 | CDK7 (0.52) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799579 | 0.89 | CDK7 (0.58) | CDK7CDK2CCNCCDK8DYRK1A | |
| SCHEMBL15799578 | 0.89 | CDK7 (0.58) | CDK7CDK2CCNCCDK8DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-09-24 | — | — | US | claimed |
| EP-2928893-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-09-24 | — | — | US | disclosed |
| WO-2014090692-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014090692-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | RB1, TP53, BRD4 | CDK7 75/4885CDK2 10/4885CCNC 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.